• 2025.12.16 (Tue)
  • All articles
  • LOGIN
  • JOIN
Global Economic Times
APEC2025KOREA가이드북
  • Synthesis
  • World
  • Business
  • Industry
  • ICT
  • Distribution Economy
  • Well+Being
  • Travel
  • Eco-News
  • Education
  • Korean Wave News
  • Opinion
  • Arts&Culture
  • Sports
  • People & Life
  • Column
    • Cho Kijo Column
    • Lee Yeon-sil Column
    • Ko Yong-chul Column
    • Cherry Garden Story
  • Photo News
  • New Book Guide
MENU
 
Home > Synthesis

Blood cancers: Lymphoma most common, multiple myeloma on the rise

Desk / Updated : 2025-02-22 07:53:55
  • -
  • +
  • Print

Lymphoma is the most common type of blood cancer, but multiple myeloma is rapidly increasing. Lymphoma is a tumor that develops in lymphocytes, a type of white blood cell, while multiple myeloma is a tumor that develops in the bone marrow. Unlike acute leukemia, lymphoma and multiple myeloma have stages. Myeloproliferative neoplasms can also develop into acute leukemia.

Lymphoma is the most common blood cancer

Lymphoma is divided into two main types: Hodgkin's lymphoma and non-Hodgkin's lymphoma. According to Professor Park Young-hoon of the Department of Hematology at Ewha Mokdong Hospital, Hodgkin's lymphoma is more common in people in their 20s, while non-Hodgkin's lymphoma is more common in people in their 50s. After the age of 60, Hodgkin's lymphoma increases again. Overall, non-Hodgkin's lymphoma accounts for about 95% of all cases, with the rest being Hodgkin's lymphoma.

Symptoms of lymphoma include swollen lymph nodes, especially in the jaw, clavicle, and groin. The swollen lymph nodes are usually painless and feel firm to the touch. Professor Park says that if you experience these symptoms along with weight loss and night sweats, you should suspect lymphoma.

Diagnosing lymphoma requires a comprehensive examination of the lymph node tissue. Therefore, it may be difficult to get an accurate diagnosis at a local clinic or small hospital. If you suspect lymphoma, it is best to get a thorough examination at a large hospital.

Treatment for lymphoma varies depending on the stage and type of lymphoma. In general, chemotherapy is used. However, if Hodgkin's lymphoma is confined to a very small area, radiation therapy may be used instead. When chemotherapy is used, high-dose chemotherapy drugs are used to kill even the smallest cancer cells. This can kill all the cells that make blood. For this reason, hematopoietic stem cells are extracted from the patient before chemotherapy and transplanted back after chemotherapy is completed.

Recently, CAR-T cell therapy, a so-called 4th generation treatment, is also being used in some cases. The complete remission rate for lymphoma is 70-80%. However, about 15% of patients experience a recurrence. The overall cure rate for lymphoma is 50-60%.

Multiple myeloma is increasing rapidly

Multiple myeloma is the fastest growing type of blood cancer in Korea. The cause is unknown, but it is thought to be related to genetic mutations and aging. Multiple myeloma develops over a long period of time. It can progress to multiple myeloma after an asymptomatic stage that shows no symptoms.

Multiple myeloma is a cancer that develops in plasma cells. Plasma cells are a type of white blood cell that is involved in the production of antibodies. When these plasma cells turn into cancer, abnormal antibodies are produced. These abnormal antibody덩어리 invade and melt the bones, causing fractures. They can also cause kidney failure and anemia.

Multiple myeloma is diagnosed through a bone marrow examination and other tests. Many patients are misdiagnosed with herniated discs or spinal stenosis and are later found to have multiple myeloma. Professor Park says that if an X-ray or MRI scan shows that the bones are melting, multiple myeloma may be suspected. The same is true if there is a compression fracture without severe osteoporosis. If you have anemia, proteinuria, poor kidney function, or back pain for no reason during a health checkup, you should be tested for multiple myeloma.

Treatment for multiple myeloma includes chemotherapy. In this case, as with lymphoma, autologous hematopoietic stem cell transplantation is often performed. However, if the patient's health is too poor or is over 70 years old, autologous hematopoietic stem cell transplantation is difficult, so only chemotherapy is performed.

Multiple myeloma is a difficult disease to cure. In the early 2000s, the survival rate was only 1-2%. Today, the survival rate is close to 50%. Professor Park says that relapses are frequent, so even if the patient is thought to be cured, they often have to be treated again. It is a disease that requires continuous monitoring.

Myeloproliferative neoplasms can be controlled with medication

Mutations in certain genes can cause hematopoietic stem cells to be produced abnormally. In this case, the number of red blood cells, white blood cells, and platelets increases, which is called myeloproliferative neoplasm. If abnormalities are found in a blood test, it is diagnosed through genetic mutation and bone marrow examination.

Myeloproliferative neoplasms are divided into four types: polycythemia vera, thrombocythemia, primary myelofibrosis, and chronic myelogenous leukemia. Symptoms and treatments vary depending on the type. Professor Lee Se-won of the Department of Hematology at Ewha Mokdong Hospital says that appropriate treatment can prevent the disease from worsening.

Symptoms of polycythemia vera include a red face. As the number of red blood cells increases, there is a risk of thrombosis and heart failure. To prevent this, low-dose aspirin is prescribed. Symptoms of thrombocythemia include frequent bruising. In this case, aspirin is prescribed to prevent thrombosis, or drugs are administered to control platelet levels.

In primary myelofibrosis, the bone marrow becomes fibrotic, and the function of making blood does not work properly. This causes anemia. The quality of life can be greatly reduced, as frequent blood transfusions are required. If the disease is left untreated, about 10% of patients develop acute myelogenous leukemia within 10 years. Professor Lee adds that with many good drugs available, primary myelofibrosis and chronic myelogenous leukemia can be prevented from developing into acute leukemia for life if properly managed. Currently, the survival rate for chronic myelogenous leukemia is over 90%.

[Copyright (c) Global Economic Times. All Rights Reserved.]

  • #globaleconomictimes
  • #글로벌이코노믹타임즈
  • #한국
  • #중기청
  • #재외동포청
  • #외교부
  • #micorea
  • #mykorea
  • #newsk
  • #nammidonganews
  • #singaporenewsk
Desk
Desk

Popular articles

  • Korean Fashion Brands Set Sights on China: Dunst Opens Pop-up in Shanghai

  • Alliance in a Dilemma: The Fallout of Trump's Advice to Takaichi Not to 'Provoke Taiwan' 

  • South Korea Lauded as 'Model Ally' After Committing to 3.5% GDP Defense Spending

I like it
Share
  • Facebook
  • X
  • Kakaotalk
  • LINE
  • BAND
  • NAVER
  • https://globaleconomictimes.kr/article/1065567091178546 Copy URL copied.
Comments >

Comments 0

Weekly Hot Issue

  • End-of-Year Concert Extravaganza: Jo Sumi, Geum Nan-sae, and Danny Koo Headline Diverse Lineup
  • R.E.D. Sectors Poised for Growth in 2026, the Year of the 'Red Horse,' Driven by AI Investment Boom
  • South Korea Launches $115 Million Export Voucher Program to Boost SME Global Reach
  • Extension Granted for '2026 Honors for SME Contributors' Application
  • 44% of Recent Construction Projects Report Deficits, Industry Survey Finds
  • South Korean AI Models Flunk College Entrance Math Exams, Lagging Far Behind Global Leaders

Most Viewed

1
Choi Bun-do, Chairman of PTV Group, Assumes Presidency of the Korean Chamber of Commerce and Industry in South Central Vietnam
2
From Court to Content: French Tennis Star Océane Dodin Trades Racquet for OnlyFans, Eyes $5M in a Year
3
Lee Dismisses Vice Minister Amid Allegations of Misconduct and Vetting Gaps
4
NVIDIA Lobby Succeeds? U.S. Bill Expected to Drop AI Chip Export Restrictions
5
US Layoffs Surge: Over 1.17 Million Job Cuts Announced in First 11 Months of 2025
광고문의
임시1
임시3
임시2

Hot Issue

South Korean AI Models Flunk College Entrance Math Exams, Lagging Far Behind Global Leaders

KRX Temporarily Slashes Stock Trading Fees by 20-40% to Counter ATS Rival

Israel Condemns Australia After Sydney Shooting, Citing 'Fueling' of Anti-Semitism

Lotte Mart Launches Major Imported Fruit Discount Event Amid High Prices

Let’s recycle the old blankets in Jeju Island’s closet instead of incinerating them.

Global Economic Times
korocamia@naver.com
CEO : LEE YEON-SIL
Publisher : KO YONG-CHUL
Registration number : Seoul, A55681
Registration Date : 2024-10-24
Youth Protection Manager: KO YONG-CHUL
Singapore Headquarters
5A Woodlands Road #11-34 The Tennery. S'677728
Korean Branch
Phone : +82(0)10 4724 5264
#304, 6 Nonhyeon-ro 111-gil, Gangnam-gu, Seoul
Copyright © Global Economic Times All Rights Reserved
  • 에이펙2025
  • APEC2025가이드북TV
  • 독도는우리땅
Search
Category
  • All articles
  • Synthesis
  • World
  • Business
  • Industry
  • ICT
  • Distribution Economy
  • Well+Being
  • Travel
  • Eco-News
  • Education
  • Korean Wave News
  • Opinion
  • Arts&Culture
  • Sports
  • People & Life
  • Column 
    • 전체
    • Cho Kijo Column
    • Lee Yeon-sil Column
    • Ko Yong-chul Column
    • Cherry Garden Story
  • Photo News
  • New Book Guide
  • Multicultural News
  • Jobs & Workers